IBA101 / Liminatus, InnoBation Bio - LARVOL DELTA

Liminatus Pharma Announces Planned Phase 1 Clinical Trial of IBA101, a Next-Generation CD47 Blocking Antibody (GlobeNewswire) - "The planned Phase 1 study is designed as a seamless clinical program, beginning with monotherapy dose escalation to evaluate safety, tolerability, and pharmacokinetics, followed by combination cohorts with PD-1/PD-L1 therapies within the same protocol....Lung cancer has been selected as the initial focus of the Phase 1 program, reflecting the Widespread use of PD-1/PD-L1 inhibitors in current treatment paradigms and the ongoing need to improve depth and durability of patient responses."

New P1 trial • Non Small Cell Lung Cancer

Liminatus Pharma LLC and Iris Acquisition Corp to combine to incorporate and accelerate much-needed cancer treatments (Businesswire) - "Liminatus Pharma LLC...and Iris Acquisition Corp...announced they have entered into a definitive business combination agreement. Upon closing of the transaction, the combined company will be renamed 'Liminatus Pharma, Inc.'....As part of the agreement the new entity is expected to develop three much-needed cancer treatments which have originated from the Thomas Jefferson University (TJU) in the US and a South Korean biotech firm, Innobation Bio Ltd. ('Innobation')....The immune-modulating cancer treatments being developed by Liminatus are a GCC Vaccine, GCC CAR-T therapy and a CD47 immune checkpoint inhibitor....The transaction is expected to be completed in the first half of 2023."

Commercial • Licensing / partnership • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor